Advertisement
Screener

CLIMB BIO, INC. (CLYM) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

CLIMB BIO, INC. Increase (Decrease) in Accrued Liabilities

CLIMB BIO, INC. (CLYM) reported Increase (Decrease) in Accrued Liabilities of $2.04 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2025-05-14

  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was $2.04M.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2024-12-31 was $1.02M, a 52.84% increase year-over-year.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2024-09-30 was $95.00K.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2024-06-30 was $1.07M.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $1.45M.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$2.61M, a 714.82% decline from fiscal 2022.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $425.00K, a 86.72% decline from fiscal 2021.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities for fiscal 2021 was $3.20M, a 231.95% increase from fiscal 2020.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accrued Liabilities 12 monthIncrease (Decrease) in Accrued Liabilities 12 month as first filed
2025-03-31$2.04M
10-Q · filed 2025-05-14
$3.06M
derived: sum of 2 quarters · filed 2025-05-14
$3.15M
derived: sum of 3 quarters · filed 2025-05-14
$4.22M
derived: sum of 4 quarters · filed 2025-05-14
2024-12-31$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25
$1.12M
derived: sum of 2 quarters · filed 2025-03-25
$2.19M
derived: sum of 3 quarters · filed 2025-03-25
$1.45M
10-K · filed 2025-03-25
2024-09-30$95.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$1.17M
derived: sum of 2 quarters · filed 2024-11-12
$421.00K
10-Q · filed 2024-11-12
$1.09M
derived: sum of 4 quarters · filed 2025-05-14
2024-06-30$1.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$326.00K
10-Q · filed 2024-08-14
$996.00K
derived: sum of 3 quarters · filed 2025-05-14
$505.00K
derived: sum of 4 quarters · filed 2025-05-14
2024-03-31-$745.00K
10-Q · filed 2025-05-14
-$75.00K
derived: sum of 2 quarters · filed 2025-05-14
-$566.00K
derived: sum of 3 quarters · filed 2025-05-14
-$1.90M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$670.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25
$179.00K
derived: sum of 2 quarters · filed 2025-03-25
-$1.15M
derived: sum of 3 quarters · filed 2025-03-25
-$2.61M
10-K · filed 2025-03-25
2023-09-30-$491.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$1.82M
derived: sum of 2 quarters · filed 2024-11-12
-$3.28M
10-Q · filed 2024-11-12
-$2.67M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$1.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$2.79M
10-Q · filed 2024-08-14
-$2.18M
derived: sum of 3 quarters · filed 2024-08-14
-$3.84M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$1.46M
10-Q · filed 2024-05-15
-$846.00K
derived: sum of 2 quarters · filed 2024-05-15
-$2.51M
derived: sum of 3 quarters · filed 2024-05-15
-$2.00M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$613.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$1.05M
derived: sum of 2 quarters · filed 2024-03-28
-$544.00K
derived: sum of 3 quarters · filed 2024-03-28
$425.00K
10-K · filed 2024-03-28
2022-09-30-$1.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$1.16M
derived: sum of 2 quarters · filed 2023-11-14
-$188.00K
10-Q · filed 2023-11-14
$1.22M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$503.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$1.47M
10-Q · filed 2023-08-10
$1.49M
10-Q · filed 2022-08-15
$2.88M
derived: sum of 3 quarters · filed 2023-08-10
$2.26M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$969.00K
10-Q · filed 2023-05-11
$899.00K
10-Q · filed 2022-05-16
$2.38M
derived: sum of 2 quarters · filed 2023-05-11
$1.76M
derived: sum of 3 quarters · filed 2023-05-11
$3.53M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$1.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
$789.00K
derived: sum of 2 quarters · filed 2023-03-06
$2.56M
derived: sum of 3 quarters · filed 2023-03-06
$3.20M
10-K · filed 2023-03-06
$3.37M
10-K · filed 2022-03-07
2021-09-30-$620.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$1.15M
derived: sum of 2 quarters · filed 2022-11-14
$1.79M
10-Q · filed 2022-11-14
$1.76M
10-Q · filed 2021-11-08
$2.14M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$1.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$2.41M
10-Q · filed 2022-08-15
$2.76M
derived: sum of 3 quarters · filed 2022-08-15
$2.99M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$637.00K
10-Q · filed 2022-05-16
$990.00K
derived: sum of 2 quarters · filed 2022-05-16
$1.22M
derived: sum of 3 quarters · filed 2022-05-16
2020-12-31$353.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07
$583.00K
derived: sum of 2 quarters · filed 2022-03-07
$964.00K
10-K · filed 2022-03-07
2020-09-30$230.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$611.00K
10-Q · filed 2021-11-08
2020-06-30$381.00K
10-Q · filed 2021-09-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Verastem, Inc. (VSTM)United States$0.706B-1.71
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Neurogene Inc. (NGNE)$0.625B-4.46
Faeth Therapeutics, Inc. (FTH)United States$0.750B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47